• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Better Therapeutics Inc.

    5/23/24 2:26:57 PM ET
    $BTTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BTTX alert in real time by email
    POS AM 1 d834667dposam.htm POS AM POS AM

    As filed with the Securities and Exchange Commission on May 23, 2024.

    Registration No. 333-276030

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO:

    Form S-1

    Registration No. 333-276030

    UNDER

    THE SECURITIES ACT OF 1933

     

     

    BETTER THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   2834   85-3472546

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification Number)

    548 Market Street, #49404

    San Francisco, CA 94104

    (415) 887-2311

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

     

    Craig R. Jalbert

    548 Market Street, #49404

    San Francisco, CA 94104

    (415) 887-2311

    (Name, address, including zip code and telephone number, including area code, of agent for service)

     

     

    Copies to:

    Sam Zucker, Esq.

    Shoaib Ghias, Esq.

    Goodwin Procter LLP

    Three Embarcadero Center

    San Francisco, CA 94111

    (415) 733-6000

     

     

    Approximate date of commencement of proposed sale to the public: This post-effective amendment is being filed to deregister all of the unsold securities previously registered under the Registration Statement.

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

    If this form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    If this form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer   ☐    Accelerated filer   ☐
    Non-accelerated filer   ☒    Smaller reporting company   ☒
         Emerging growth company   ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     


    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 relates to the following Registration Statement on Form S-1 (the “Registration Statement”), filed with the Securities Exchange Commission (the “SEC”) by Better Therapeutics, Inc. (the “Registrant”):

     

      •  

    Registration Statement No. 333-276030, originally filed with the SEC on December  13, 2023, as amended by Amendment No. 1 on December  18, 2023, Amendment No. 2 on December  21, 2023, Amendment No. 3 on December 27, 2023.

    The Registrant is filing this Post-Effective Amendment to deregister any and all securities that remain unsold under the Registration Statement as of the date hereof. In accordance with the undertakings made by the Registrant in the Registration Statement to remove from registration by means of a post-effective amendment any securities that had been registered for issuance but remain unsold at the termination of the offering, the Registrant hereby removes and withdraws from registration any and all securities registered pursuant to the Registration Statement that remain unsold as of the date hereof.


    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-1 and has duly caused this Post-Effective Amendment to the Registration Statement on Form S-1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Francisco, State of California, on May 23, 2024.

     

    BETTER THERAPEUTICS, INC.
    By:  

    /s/ Craig R. Jalbert

      Craig R. Jalbert, Chief Executive Officer

    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.

    Get the next $BTTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BTTX

    DatePrice TargetRatingAnalyst
    11/24/2021$17.00Buy
    Chardan Capital Markets
    11/10/2021Outperform
    Cowen
    More analyst ratings

    $BTTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital Markets initiated coverage on Better Therapeutics with a new price target

      Chardan Capital Markets initiated coverage of Better Therapeutics with a rating of Buy and set a new price target of $17.00

      11/24/21 7:14:30 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on Better Therapeutics

      Cowen initiated coverage of Better Therapeutics with a rating of Outperform

      11/10/21 6:22:09 AM ET
      $BTTX
      Biotechnology: Pharmaceutical Preparations
      Health Care